Copyright © Inderes 2011 - present. All rights reserved.
  • Senaste
  • Börs
    • Aktiejämförelse
    • Börskalender
    • Utdelningskalender
    • Aktieanalys
    • Artiklar
  • InderesTV
  • Portfölj
  • Forum
  • Q&A
  • Om oss
    • Bolag under bevakning
    • Teamet

Du verkar använda en bredare skärm. Vill du aktivera en bredare visningsupplevelse på denna sida?

Embla Medical – Presentation of Q4 2024

Av HC Andersen Capital
Embla Medical

You can already now sign up for the event and send in your questions. You don’t have to participate live to submit questions for the event.

Embla Medical will release its Q4 2024 interim report on 5 February 2025. The same day at 11.00, the company’s management will present the results and answer questions in an online live event. Besides the financial results, you can get an update on the recent business and regulatory developments.

For the first nine months of 2024, Embla Medical realized an organic growth of 7% (10% including acquisitions) and an EBITDA margin of 20%. The first nine months of 2024 were in line with the full-year guidance that the company reiterated in connection with the Q3 2024 report. For the full year 2024, Embla Medical expects 6-8% organic growth and an EBITDA margin before special of approx. 20%.

In connection with the Q4 report, we expect that the focus will be on the 2025 guidance. 2025 will be the first full year with the effects of the positive changes to the US reimbursement and the second year in Embla Medical’s Growth’27 strategy period with the ambition of annual revenue growth of 7-10% both organically and through acquisitions, with gradually increasing EBITDA margins.

Embla Medical is a leading global provider of innovative mobility solutions in the medical technology space. Embla Medical improves people’s mobility through the delivery of Prosthetics & Neuro Orthotics, Bracing & Supports, and Patient Care.

Dislcaimer: HC Andersen Capital receives payment from Embla Medical for a Corporate Visibility/Digital IR subscription agreement. /Michael Friis, 09.22, 9 January 2025.

Recent videos

Talenom - Planned demerger and strategies of Talenom and Easor
2025-12-18 11:00 Talenom
Conference call with Fabege´s new CEO Bent Oustad
2025-12-18 10:00 Fabege
Investing in the life science sector
2025-12-18 07:47
Life Science Companies as Investments | Life Science Night Dec. 9, 2025
2025-12-16 08:30 Aiforia Technologies
Truecaller, Webcast, Press Conference, 2025
2025-12-15 13:00 Truecaller
Titta på alla videos
Följ oss på våra kanaler i social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Ta kontakt
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • Om oss
  • Teamet
  • Jobba hos oss
  • Inderes som en investering
  • Tjänster för börsbolag
Vår plattform
  • FAQ
  • Servicevillkor
  • Integritetspolicy
  • Disclaimer
Inderes disclaimer gällande utförda aktieanalyser kan läsas här. För mer detaljerad information över de aktier som aktivt bevakas av Inderes, vänligen se respektive bolags bolagsspecifika sida på Inderes webbplats. © Inderes Oyj. Alla rättigheter förbehållna.